Peptinovo Biopharma
Company Details
Status: Private
Employees: 1-10
Location:
600 S Wagner Road, Ann Arbor, MI, US
Type:
sample
Technology:
sample
About: Chemotherapy is the foundation of cancer treatment because it is so effective, but it is also the downfall of cancer treatment because it is so toxic. Patients can experience hair loss, nausea, fatigue, aching, or neuropathy and often find that the treatment seems worse than the disease. Imagine the impact a technology would have on cancer treatment if that technology maintains or even improves the efficacy of established chemotherapies without the harmful side effects. And that is what Peptinovo aims to do.
Peptinovo Biopharma Inc. has invented and patented a targeted, drug-delivery platform: Peptide-Amphiphile Lipid Micelle (PALM) that reduces or eliminates chemotherapy-induced peripheral neuropathy (CIPN), one of the most serious side effects threatening treatment outcomes for world-leading chemotherapy drugs like paclitaxel. PALM delivers higher doses of proven drugs INTO tumors, keeping them AWAY from healthy tissues. Lives are extended and side effects are avoided.
Peptinovo is developing its first platform, PNB-281, to eliminate the nerve damage caused by paclitaxel against many major cancers including breast, ovarian, lung, prostate, and pancreatic cancers. Nerve damage is the most serious side-effect threatening the ability to complete the cancer treatment.
Peptinovo's technology can be used to treat many cancers and it can be used with many chemotherapy drugs.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Peptinovo Biopharma | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.